Navigation Links
New Study Shares Best Practices in Biopharma Public Relations
Date:11/6/2008

CHAPEL HILL, N.C., Nov. 6 /PRNewswire/ -- While Public Relations has long been used as a marketing tool by the pharmaceutical and biotechnology industries, its ability to reach consumers has never been greater. Web sites, online social networks, and blogs have joined the traditional press release as effective and low-cost methods that help drive sales. With this understanding, new research was conducted by Best Practices, LLC to identify what Public Relations activities are most effective at educating and informing consumers at different points in a product's lifecycle. These and other insights are now available in the newly published report, "Public Relations Excellence: Using PR to Launch, Grow and Extend Your Brands." Additional findings from this study include insights into what Public Relations channels, tactics and calls-to-action are most effective for reaching consumers of pharmaceutical products while providing three case studies highlighting successfully employed Public Relations tactics at different lifecycle stages.

To view the study abstract or complimentary summary of the full report "Public Relations Excellence: Using PR to Launch, Grow and Extend Your Brands," click on the following link http://www3.best-in-class.com/rr975.htm .

In a benchmarking study that included such influential companies as Abbott, AstraZeneca, Genentech, Johnson & Johnson, Novartis, Pfizer, and Wyeth, many key topics were covered, including:

-- PR strategies and tactics that are most effective at different

lifecycle stages

-- PR tools and calls to action that are most effective

-- Case studies that reveal effective PR practices

-- Web site resources that are most effective for consumers

-- Ideal budget ratios and performance measurements

-- Lessons learned and best practices

For more information on this report, contact Robert Naylo
'/>"/>

SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 Topical BioMedics, Inc., is celebrating ... end their suffering, restoring hope an quality of life ... only possible because of the innovative cellular biomedicines research ... a reality. , The company was founded in ... Paradise (president, chief of research, and Topricin inventor), Aurora ...
(Date:9/22/2014)... , Sept. 22, 2014 Research ... "Global and Chinese Microcrystalline Cellulose Industry Report 2014" ... Global and Chinese Microcrystalline Cellulose Industry Report 2014 is ... of the global microcrystalline cellulose industry with a focus ... a basic overview of the industry including definitions, classifications, ...
(Date:9/22/2014)... LANSING, Mich., Sept. 22, 2014  Neogen Corporation (Nasdaq: ... for the first quarter of its 2015 fiscal year, ... increase compared to net income of $7,839,000 in the ... stock split effective Oct. 30, 2013, earnings per share ... a year ago. First quarter revenues increased ...
(Date:9/22/2014)... , September 22, 2014 ... on a mixed note as the Dow Jones Industrial ... Composite closed at 4,579.79, down 0.30%. The S&P 500 ... trading session, six out of ten sectors finished on ... Index ended the day at 751.48, up 0.10%, with ...
Breaking Biology Technology:Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
... interesting meeting took place this past week at the University ... The focus of the meeting was an opportunity to hear ... last annual BIO meetings in different cities, as a preview ... this Olympics of Biotechnology meeting comes to Chicago in April, ...
... hit a nerve. , , I heard from a number ... 2.0 is spelled b-u-b-b-l-e, and who want none of it. As ... use a healthy dose of caution to prevent the heavy Kool-Aid ... group. , ,Indeed, in dozens of conversations with start-ups seeking a ...
... and after its recent redesign The Internal Revenue Service ... well as tweaking its search engine to hopefully make it easier ... keeping roughly the same design since mid-2002, the IRS decided to ... Among other features, the site has links to the most-requested publications ...
Cached Biology Technology:The legacy of BIO 2006, what it will be and how we need to plan for it now 2The legacy of BIO 2006, what it will be and how we need to plan for it now 3The legacy of BIO 2006, what it will be and how we need to plan for it now 4The legacy of BIO 2006, what it will be and how we need to plan for it now 5The legacy of BIO 2006, what it will be and how we need to plan for it now 6Can we prevent Web 2.0 from being a bubble? 2Can we prevent Web 2.0 from being a bubble? 3
(Date:9/22/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... mobile commerce market, issues the following corporate shareholder update ... Letter from the CEO : ... funding and joined the NASDAQ to support ramping of ... biometric and authentication products and services. This strategic achievement positions ...
(Date:9/21/2014)... significantly less likely to report taking iron supplements before ... who are developing normally, a study by researchers with ... iron intake was associated with a five-fold greater risk ... 35 or older at the time of the child,s ... as obesity hypertension or diabetes. , The research is ...
(Date:9/21/2014)... at the University of California, San Diego, have developed ... that control the activity of genes based on sequences ... from its application to human embryonic cells in a ... 21. , "All of our cells have the same ... said John Whitaker, lead author of the report. "Skin ...
Breaking Biology News(10 mins):NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4Mothers of children with autism less likely to have taken iron supplements 2Program predicts placement of chemical tags that control gene activity 2
... Shire plc (LSE: SHP)(NASDAQ: SHPGY ), the ... approved,the scheme of arrangement between Shire plc and ... which becomes effective on 23 May 2008,results in ... SHP,NASDAQ: SHPGY) becoming the new holding company for ...
... CORVALLIS, Ore. An international team of scientists surveying ... Coast of North America has discovered for the first ... miles of the shoreline, raising concern for marine ecosystems ... an Oregon State University research vessel, also discovered that ...
... called FIGLA cause premature ovarian failure in at least a ... from Baylor College of Medicine in Houston and Shandong University ... the American Journal of Human Genetics. We hope to ... genes associated with this problem to find biomarkers in blood ...
Cached Biology News:Court Approves Scheme of Arrangement 2Court Approves Scheme of Arrangement 3Pacific coast turning more acidic 2Pacific coast turning more acidic 3Oocyte-specific gene mutations cause premature ovarian failure 2
...
... SpliceArray service, ExonHit can design custom microarrays ... your gene list. Proprietary algorithms are ... microarray probes from high quality, spliced cDNAs ... event contained in a custom SpliceArray is ...
... binding specificity and signaling of the members ... be modified by alternative splicing--which has important ... you can perform a classical expression profiling ... different alternatively spliced forms of the gene ...
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
Biology Products: